Company announcements · 09/11/20261 min read
Zemcelpro® (UM171 Cell Therapy) licensing and supply agreements announced for Europe
Summary
Partnership advances the global commercialization strategy for Zemcelpro® (dorocubicel), also known as UM171 Cell Therapy, following its conditional marketing authorisation in Europe from the European Commission.
Original source language: PR Newswire UK — News ReleasesOpen original release →
Related companies